Health Catalyst (HCAT)
(Real Time Quote from BATS)
$6.64 USD
-0.01 (-0.15%)
Updated May 9, 2024 10:36 AM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
HCAT 6.64 -0.01(-0.15%)
Will HCAT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HCAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCAT
Sonendo, Inc. (SONX) Reports Q1 Loss, Tops Revenue Estimates
Health Catalyst (HCAT) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
HCAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
Other News for HCAT
Health Catalyst Q1 2024 Earnings Preview
Analysts’ Top Healthcare Picks: Health Catalyst (HCAT), Sartorius (GB:0NIQ)
Health Catalyst to Announce First Quarter 2024 Operating Results and Host Conference Call on Thursday, May 9, 2024
HROW, HCAT and EGRX are among after hour movers
R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space